ASH 2013: Obinutuzumab Beats Rituximab in Older CLL Patients

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL), obinutuzumab outperformed rituximab in both response rate and progression free survival (PFS), suggesting that rituximab may no longer be at the top of every blood cancer-based treatment totem pole.

This information was presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

Like rituximab, obinutuzumab (otherwise known as GA101) is an anti-CD20 monoclonal antibody. Traditionally, although rituximab is a star against many blood cancers, it has never been especially effective in older CLL patients.

The trial

The trial randomized 781 patients into one of three treatment arms:

  • Chlorambucil (118 patients)
  • Chlorambucil plus rituximab (330 patients)
  • Chlorambucil plus obinutuzumab (333 patients)

The trial's primary endpoint was PFS, and those patients in the treatment arm had a median PFS of 26.7 months, compared to 15.2 months for patients receiving rituximab.

Complete response rate in the treatment arm was superior as well, with a rate of 21 percent, compared to just 7 percent in the rituximab arm.

These results, presented by Valentin Goede, M.D., of the Center of Integrated Oncology Cologne-Bonn at the University Hospital Cologne in Germany, are not necessarily going to translate for younger patients, and this treatment has not been tested in that setting.

"We can say that obinutuzumab will replace rituximab in the treatment of elderly CLL patients when combined with a weaker chemotherapy backbone," Goede concluded.

Source: ASH

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...